Clinical Trials
118 trialsPOLARIX
Hoffmann-La Roche
Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
Pharmacyclics LLC.
S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma
SWOG Cancer Research Network
CRISTALLO
Hoffmann-La Roche
Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients
Gustave Roussy, Cancer Campus, Grand Paris
POLARGO
Hoffmann-La Roche
Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment
Goethe University
CHRONOS-3
Bayer
RELEVANCE
The Lymphoma Academic Research Organisation
Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
Universität des Saarlandes
A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
Incyte Corporation
MAGNIFY
Celgene
A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma
Janssen Research & Development, LLC
SELENE
Janssen Research & Development, LLC
RELEVANCE
Celgene
PACIFICO
University of Liverpool
R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL
The Lymphoma Academic Research Organisation
A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
Janssen Research & Development, LLC
Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)
Institut Curie
FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia
German CLL Study Group
GAIA
German CLL Study Group
Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A
Hoffmann-La Roche
Rinomax
Karolinska Institutet
Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma
University of Nebraska
ILyAD
University of Rochester
Bendamustine Plus Rituximab Versus CHOP Plus Rituximab
University of Giessen
Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab
University of Giessen
Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia
University of Ulm
Rituximab in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma
University College, London
Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma
Eastern Cooperative Oncology Group
FLINTER
Dr. Reddy's Laboratories Limited
A Study Comparing SIBP-02 and Rituximab Combination With CHOP in Previously Untreated Subjects With CD20+ DLBCL
Shanghai Institute Of Biological Products
MADILYM
Mabion SA
MURANO
Hoffmann-La Roche
Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Canadian Cancer Trials Group
ROBUST
Celgene
Phase III Study of SyB L-0501 in Combination With Rituximab to Treat Recurrent/Relapsed Diffuse Large B-Cell Lymphoma
SymBio Pharmaceuticals
AUGMENT
Celgene
Radiotherapy Versus Radiotherapy Plus Chemotherapy in Early Stage Follicular Lymphoma
Trans Tasman Radiation Oncology Group
JASMINE
Amgen
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
Hoffmann-La Roche
Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma
Fondazione Italiana Linfomi - ETS
Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCL
Shanghai Henlius Biotech
PIX-R
CTI BioPharma
BMTCTN0401
National Heart, Lung, and Blood Institute (NHLBI)
Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma
Universität des Saarlandes
ASSIST_FL
Sandoz
Efficacy of Lenalidomide in Combination With Subcutaneous Rituximab + miniCHOP in DLBCL Patients of 80 y/o or+
The Lymphoma Academic Research Organisation
To Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma
Celltrion
Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma
German High-Grade Non-Hodgkin's Lymphoma Study Group